NCT06231017View on ClinicalTrials.gov

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

January 19, 2025

Study Completion Date

January 19, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Adebrelimab + Cetuximab+ Chemotherapy

Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER